Literature DB >> 7778854

Interleukin-6 and interleukin-1 receptor antagonist in acute stroke.

N B Beamer1, B M Coull, W M Clark, J S Hazel, J R Silberger.   

Abstract

Elevated plasma levels of interleukin-6 (IL-6), a key regulator of the acute phase response that includes increased fibrinogen synthesis, have recently been detected in patients with acute stroke. Nevertheless, the role of the acute phase response in stroke has been controversial, with some studies suggesting that preexisting infection accounts for most of the acute phase response. Increased IL-6 could signal the involvement of antiinflammatory activity, since IL-6 stimulates the production of endogenous antiinflammatory mediators such as interleukin-1 receptor antagonist (IL-1RA). To better understand the interaction of pro- and antiinflammatory acute phase processes in brain infarction, plasma levels of IL-1RA, IL-6, and acute phase proteins including fibrinogen and c-reactive protein (CRP) were measured within 4 +/- 2 days of onset in 50 patients with acute ischemic stroke and in 20 age-matched healthy controls. After excluding patients with evidence of infection, both IL-1RA and IL-6 were significantly elevated in stoke patients compared with controls (p < 0.0001). IL-1RA and IL-6 were both significantly correlated with levels of CRP, p < 0.05 and p < 0.001, respectively, but not with each other. Levels of IL-6 and IL-1RA, together with fibrinogen and CRP were higher in patients with infarcts of greater than 3 cm and lowest in patients with lacunar syndromes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7778854     DOI: 10.1002/ana.410370614

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  41 in total

Review 1.  The immunology of acute stroke.

Authors:  Ángel Chamorro; Andreas Meisel; Anna M Planas; Xabier Urra; Diederik van de Beek; Roland Veltkamp
Journal:  Nat Rev Neurol       Date:  2012-06-05       Impact factor: 42.937

Review 2.  Modulation of the postischemic immune response to improve stroke outcome.

Authors:  Kyra J Becker
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

3.  Neuronal over-expression of ACE2 protects brain from ischemia-induced damage.

Authors:  Ji Chen; Yuhui Zhao; Shuzhen Chen; Jinju Wang; Xiang Xiao; Xiaotang Ma; Madhuri Penchikala; Huijing Xia; Eric Lazartigues; Bin Zhao; Yanfang Chen
Journal:  Neuropharmacology       Date:  2014-01-15       Impact factor: 5.250

4.  Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke.

Authors:  M Kouwenhoven; C Carlström; V Ozenci; H Link
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

5.  Post-stroke infection: a role for IL-1ra?

Authors:  Pat Tanzi; Kevin Cain; Angela Kalil; Dannielle Zierath; Anna Savos; J Michael Gee; Dean Shibata; Jessica Hadwin; Kelly Carter; Kyra Becker
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

6.  Interleukin 6-preconditioned neural stem cells reduce ischaemic injury in stroke mice.

Authors:  Hiroyuki Sakata; Purnima Narasimhan; Kuniyasu Niizuma; Carolina M Maier; Takuma Wakai; Pak H Chan
Journal:  Brain       Date:  2012-11       Impact factor: 13.501

Review 7.  MicroRNAs regulate the chaperone network in cerebral ischemia.

Authors:  Yi-Bing Ouyang; Rona G Giffard
Journal:  Transl Stroke Res       Date:  2013-08-17       Impact factor: 6.829

8.  Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients.

Authors:  Tomasz Dziedzic; Elzbieta A Gryz; Wojciech Turaj; Agnieszka Slowik; Andrzej Szczudlik
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Serum interleukin-6 predicts cortisol release in acute stroke patients.

Authors:  A Szczudlik; T Dziedzic; S Bartus; A Slowik; A Kieltyka
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

10.  Evaluation of the inflammatory response in sera from acute ischemic stroke patients by measurement of IL-2 and IL-10.

Authors:  Amit R Nayak; Rajpal S Kashyap; Hemant J Purohit; Dinesh Kabra; Girdhar M Taori; Hatim F Daginawala
Journal:  Inflamm Res       Date:  2009-04-02       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.